treadmill walking performance (peak walking time and claudication onset time) and Walking Impairment Questionnaire (WIQ). We did not assess other outcomes that did not vary by treatment in the CLEVER study. 3 We excluded 7 patients of races other than black or white. Change from baseline was analyzed using linear mixed-effects models, including treatment groups, race, and follow-up time in months as fixed effects. We examined all 2-and 3-way interaction terms to test for differences in treatment response over time between race groups and used an unstructured covariance matrix to account for repeated measurements. The models were adjusted for baseline health status and baseline characteristics that differed within races or by treatment within races (age, sex, hypertension, smoking status, diabetes mellitus, arthritis/musculoskeletal disorders, stroke, myocardial infarction, and percutaneous coronary intervention).
Among 104 eligible patients, 41, 43, and 20 patients were randomized to SE, ST, and OMC, respectively. The mean age was 64.2 years, and 37.5% were women. Seventy-five patients were white (OMC, 14; SE, 25; ST, 36) and 29 were black (OMC, 6; SE, 16; ST, 7). Follow-up at 18 months was similar for white versus black (86.7% versus 89.7%, respectively) with no intervening death. At baseline, there were no significant racial differences in resting ankle-brachial index, use of antiplatelet, statin or cilostazol therapy, PAQ summary scores, SF-12 PCS, peak walking time, claudication onset time, or WIQ. However, compared with white participants, black participants were more likely to be women (55.2% versus 30.7%), current smokers (58.6% versus 52.0%), have diabetes mellitus (40.7% versus 18.7%), and arthritis/other musculoskeletal disorder (44.8% versus 22.5%). Within each racial group, there were no significant baseline differences by treatment groups in resting ankle-brachial index, PAQ summary scores, SF-12 PCS, peak walking time, claudication onset time, or WIQ.
There was a significant race-treatment interaction for PAQ summary scores (P=0.035); in white, PAQ scores increased only with ST, whereas in black, they increased with both ST and SE, compared with OMC ( Figure, top) . Interestingly, in the OMC group, PAQ score decreased over time in black but not in white. Model-estimated mean changes (95% confidence interval) in PAQ summary scores in SE and ST compared with OMC were 2.9 (−10.0 to 15.8) and 26.6 (14.6 to 38.6) in white, and 28.2 (8.7 to 47.7) and 31.8 (10.4 to 53.2) in black, respectively, which was unchanged at 6 and 18 months (P=0.22 for race-month interaction and P=0.38 for racetreatment-month interaction). A significant race-treatment interaction was also found for SF-12 PCS (P=0.005), which increased only with ST in white and only with SE in black, compared with OMC ( Figure, bottom) . Model-estimated mean changes in SF-12 PCS scores in SE and ST compared with OMC were 3.9 (−0.6 to 8.4) and 6.7 (2.5 to 10.9) in white and 15.9 (7.0 to 24.8) and 5.8 (−2.4 to 14.1) in black, respectively, which were unchanged at 6 and 18 months (P=0.28 for race-month interaction and P=0.64 for race-treatmentmonth interaction). Similarly, model-estimated changes in PAQ scores were −23.7 (−34.4 to −13.0) and −3.6 (−21.2 to 14.0) in SE compared with ST in white and black, respectively, and for SF-12, the scores were −2.8 (−6.8 to 1.2) and 10.0 (3.1 to 17.0), respectively. The race-treatment, race-month, and race-treatment-month interactions were not significant for other outcomes (all P>0.05).
COMMENT
We found that although PAD-specific health status scores were greater with both SE and ST compared with OMC in black, such difference was seen only with ST in white. Furthermore, compared with ST, PAQ summary scores were lower with SE in white but were not different in black. Compared with OMC, general health status scores were greater only with SE in black and only with ST in white. However, when compared with ST, SF-12 PCS scores were greater with SE in black but were not different in white. No significant differences were noted for treadmill walking performance or WIQ.
Although the smaller sample size reduces statistical power, the observed significant racial differences in health status may suggest racial heterogeneity in treatment responses. Should these findings be replicated in larger studies, we need to understand why SE may be more beneficial in black as compared with white. Identifying whether these differences in treatment response are mediated by psychosocial stress, economic factors, adherence, baseline exercise level, or other unknown factors could help identify opportunities to tailor PAD treatment strategies to specific racial groups or other patient-centered factors that would benefit the most. Black may have a more compromised starting situation, such as socioeconomic, mental health, or risk factor control, as seen in this study. Engaging in exercise could provide greater overall benefit in black.
A difference of 8 points in PAQ and >5 points in SF-12 is considered clinically important. 3 The observed changes in health status are clinically significant. If substantiated later, additional studies should corroborate these improvements with other clinical measures to improve interpretability. Furthermore, the Centers for Medicare and Medicaid Services recently agreed to reimburse SE programs, 5 and targeting such therapy to right patient population will be the most impactful.
The CLEVER trial enrolled selected patients with aortoiliac disease irrespective of femoropopliteal PAD. Therefore, our findings may not extend to patients with isolated femoropopliteal lesions or patients not meeting trial eligibility criteria. Despite 3 randomization arms (SE, ST, and OMC), OMC was provided in all patients, and the primary interest of the trial was to compare the effect of SE with ST.
3 So, our results require careful interpretation when considering OMC as a control.
Although some overlap between PAQ and SF-12 PCS is expected, PAQ provides PAD-specific information that SF-12 does not. We did not find significant interactions for mobility-based outcomes, like WIQ and treadmillbased measures. Although WIQ provides information on PAD-specific mobility, it does not provide other quality-of-life information. 8 Whether this explains the disparate findings requires further study.
This hypothesis-generating post hoc analysis of the CLEVER trial demonstrates differential quality-of-life ben- 
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